SCHEMBL1786825

SCHEMBL1786825

CS(=O)(=O)c1ccc2nc(NC(=O)NC(=O)c3cc(C(F)(F)F)ccc3Cl)sc2c1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 10/20 0.73
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
HPGD P15428 1/20 0.60
KDM4E B2RXH2 2/20 0.57
RECQL P46063 1/20 0.57
HSD17B10 Q99714 1/20 0.56
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
ALDH1A1 P00352 2/20 0.55
LMNA P02545 1/20 0.55
POLB P06746 1/20 0.55
MAPT P10636 1/20 0.55
HTT P42858 1/20 0.55
ATM Q13315 1/20 0.55
DYRK1A Q13627 1/20 0.54
RXFP1 Q9HBX9 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1787796 0.88 GHSR (0.77) GHSRMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL1790479 0.88 GHSR (0.80) GHSRMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL1786626 0.87 GHSR (0.79) GHSRMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL1785654 0.86 GHSR (0.77) GHSRMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL1788191 0.86 GHSR (0.77) GHSRMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL1785665 0.85 GHSR (0.75) GHSRMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL1789562 0.85 GHSR (1.00) GHSRMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL1786595 0.85 GHSR (0.85) GHSRMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL1786398 0.84 GHSR (0.73) GHSRMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL1786516 0.84 GHSR (0.73) GHSRMEN1KMT2ASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607357-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS Astrazeneca AB (SE) 2013-06-26 EP claimed
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2011-05-26 US claimed
US-20090186870-A1 Therapeutic Agents - 802 ASTRAZENECA AB (SE) 2009-07-23 US claimed
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2013-08-08 US disclosed
EP-2607357-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS Astrazeneca AB (SE) 2013-06-26 EP disclosed
US-20120115845-A1 THERAPEUTIC AGENTS ALLEN JACK MCQUEEN (GB) 2012-05-10 US disclosed
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2011-05-26 US disclosed
US-20090186870-A1 Therapeutic Agents - 802 ASTRAZENECA AB (SE) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R GHSR 2/4885MEN1 2250/4885KMT2A 1721/4885
US-20120115845-A1 THERAPEUTIC AGENTS GPR119, MC2R, MC4R GHSR 30/4885MEN1 692/4885KMT2A 3139/4885
US-20090186870-A1 Therapeutic Agents - 802 GPR119, SLC5A2, MC2R GHSR 59/4885MEN1 1253/4885KMT2A 2304/4885
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R GHSR 2/4885MEN1 2250/4885KMT2A 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.